CSL Seqirus, a business of CSL (ASX: CSL), announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health.

CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years.

CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

FLUAD® Influenza vaccine (surface antigen, inactivated, adjuvanted with MF59®) is now preferentially recommended by the Comité sur l’immunisation du Québec (Quebec Immunization Committee, or CIQ) for adults 65 years of age and older.

· CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.
· Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and livestock have been reported in the U.S.
· Fourth avian influenza pandemic preparedness award to CSL Seqirus under a multi-year agreement with Biomedical Advanced Research and Development Authority (BARDA).

Despite high burden of disease, influenza continues to suffer from perceived lack of risk, contributing to low vaccine uptake among parents and Canadian adults

Health Canada’s Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic Partner

Absolute Efficacy of Cell-Based Influenza Vaccines in Children Aged 2 to 18 Years, Impact of COVID-19 on Canadians’ Views of Influenza, Among Data Being Presented

Safeguarding our people and communities remains our top priority.

/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains¹.